Company intelligence / Profile preview

Akos Biosciences

Naples, Florida, United States

Ownership: Private
Development stage: Other

Overview

Akos Biosciences developed proprietary cannabinoid conjugate molecules, including cannabinoid-COX-2 and cannabinoid-steroid conjugates; a CBD-based lotion showed promising results in early-stage animal tests for radiation dermatitis. Assets were licensed out after a failed spin-off, and further development is via partners[3][1].

Therapeutic areas: ImmunologyDermatologyRheumatology
Modalities: Small moleculeCannabinoid-COX-2 conjugate (conjugate small molecules)Cannabinoid-steroid conjugate (conjugate small molecules)
Industry: Biotech

Drug pipeline

1 asset

Akos

Preclinical

Partnerships

Restoration Biologics (licensed joint disease assets)Aries Science & Technology (licensed topical CBD-based lotion for radiation dermatitis)

Beyond the preview

Go deeper on Akos Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akos Biosciences.

Explore the full profile